Boston Session Special Lecture

	Affiliation	Name of Speaker	Title
	**Biogen Japan Inc**	**Shinichi Torii**	**Introduction for new drug development based on Neuroscience research**
	Born in June, 1960 March, 1984 Graduated from Gifu College of Pharmacy March, 2002 Ph.D degree from Molecular Biology from Tokyo University, Graduate School April, 1984～ Janssen Pharmaceutical K.K. April, 2007～ Celgene Corporation April, 2010～ Olympus Corporation January, 2011～ Olympus Biotech Corporation (Boston, USA) June, 2014～ Head of R&D, Biogen Japan Inc. April, 2017～ President & Representative Director, Biogen Japan Inc. November, 2018～ President & Representative Director, Biogen Japan Inc. (Daihyo Torishimariyaku Kaicho)		Shinichi joined Biogen Japan in June 2014 to establish and lead its R&D function in Japan as part of Biogen's 'Tri-Hub' research and development model. He brings his depth knowledge and experience in both academia and the industry to leverage the world-class scientific innovation of Biogen. Prior to Biogen, he spent many years as a researcher in academia and expanded his career path into the pharmaceutical and medical device industries including Janssen Pharmaceutical and Olympus Biotech. In his past experiences, Neurology research and development including MS, Alzheimer's diseases and growth factors, NGF and BDNFs are one of his scientific interests as not only "bench to bed" but also "bed to bench" collaborations with Japanese basic and clinical researchers.

Boston Session Pitch Presenters

		Affiliation	Name of Speaker	Title
1		**biolabs**	**Christine Kressirer, PhD,**	**BioLabs, the experience of a biotechnology company in a shared-laboratory facility**
		1998-2002 Colorado State University BioChemistry,Microbiology 2007-2010 Ludwig-Maximilians University Munich, Doctor of Philosophy,(Ph.D),Pharmaceutical Biology and Natural Sciences		2011-2018 The Forsyth Institute Final title - Director of Core and Laboratory services 2018~ Site Director, Tufts Launchpad Biolabs
2		**UCHU Biosensors, Inc.**	**Daniel Weinstein**	**Intraoral Health Monitor**
		Co-Founder, CEO of UCHU Biosensors, Inc. 2014 - Researcher, Dana Farber Cancer Institute Studied anti-aptotic cell signaling pathways for drug development 2015 - Researcher, Tufts Sackler School of Biomedical Sciences Grew artificical skin from iPS cells to study chronic wound healing		2016 - Summer Researcher, Technion Institute of Technology Characterized and validated response of nanoscale optical biosensors 2018 - Graduated cum laude with a BSBME (bachelors of science in biomedical Engineering)from Tufts University School of Engineering
3		**Mytide Therapeutics**	**Dale A. Thomas III**	**High-throughput Peptide Manufacturing for Therapeutic Research and Drug Discovery**
		2013 B.S. Maine Maritime Academy, Valedictorian 2013 American Bureau of Shipping Fellowship 2014 MEngM, Massachusetts Institute of Technology 2019 PhD, Massachusetts Institute of Technology 2019 Cofounder, Mytide Therapeutics		
4		**DropGenie**	**Alison Hirukawa**	**Automating gene editing using a digital microfludics platform**
		2011 MSc, Medical Genetics, University of British Columbia, Vancouver, Canada		2017- PhD, Biochemistry, McGill University, Montreal, Canda 2018- Co-founder, Chief Product Officer, DropGenie, Boston MA
5		**North Shore InnoVentures**	**Christopher R.C.Ilsley**	**Innovate faster, Climb higher**
		Chris is the President and CEO of NSIV. As a leader in the Boston innovation ecosystem Chris and the team at North Shore InnoVentures (NSIV) are actively involved in supporting innovation-driven companies to realize and deliver impact. Not only does NSIV support companies through start of the art lab facilities; but, also, importantly, with business and leadership support through programs, services, community partnerships and mentoring.		NSIV is an accredited 'soft landing' facility for the International Business Incubator Association (InBIA). This accreditation validates that NSIV has a robust and supportive services and program to help international companies to enter the Boston and North American life science community. Chris moved to Boston as Head of Science and Innovation at the British Consulate Boston, from Cambridge, UK, where he worked as an advisor to UK companies looking identify and develop international partnership opportunities.
6		**Genomic Expression**	**Gitte Pedersen**	**Title: OneRNA™: a paradigm shift to truly individualized treatment**
		Scientist/CEO with a mission to cure cancer. Started Genomic Expression together with her brother, after her parents were diagnosed with cancer. The company raised $8M to conduct 4 clinical trials focusing on women cancer first. OneRNA™ finds the best drug for the patient and the best patient for the drug by sequencing RNA. Genomic Expression was in the top 10 of the XTC, also won the Lyfebulb and the EUTop50 award, and presented at the European Parliament and UN in New York.		Prior to Genomic Expression, Gitte advised a number of SMEs of biotech as well as the Danish Ministry of Foreign Affairs with deal resume +$1B. Gitte Pedersen has a master in Chemical Engineering and a bachelor in International Trade. She recently joined Pipeline Angels and made her first angel investment.
7		**Cellanyx Diagnostics**	**Guy L. Fish**	**Stratifying indolent from aggressive cancers: it's the biology, not the histology**
		1988-1992 Solo-Practice, Internal Medicine 1995-1999 The Boston Consulting Group, USA 1999-2000 Sanford Bernstein, Equities Analyst, NY, NY 2000-2001 Ivy Consulting Enterprises, Health Care Consulting, Boston, MA 2001-2002 Collagenesis, a tissue engineering firm, Boston, MA 2002-2007 Fletcher Spaght, Inc, Health Care Consulting, Director		2004-2010 Massachusetts Board of Registration in Medicine, MD Licensing Board,Chairman of Licensing 2010-2016 Dubai Health Care City Licensing Board, Chairman of Board 2005-2018 Fletcher Spaght Venture, Health Care Venture Capital, Vice President 2007-2019 Fletcher Spaght, Inc., Health Care Consulting, Senior Vice President 2019 Cellanyx Diagnostics, CEO
8		**Thrive Bioscience, Inc.**	**Thomas Forest Farb-Horch**	**Analytics, AI & Automation in Cell Culture & Stem Cell Culture**
		Mr. Farb-Horch is CEO and President of Thrive Bioscience (Boston, Massachusetts) which provides instruments and software tools for the automation of cell culture and stem cell culture, a neglected yet critical area for biomedical research. Thrive has raised $20M to-date, has filed 46 patent applications and is in beta testing of its first of a family of instruments with Harvard Stem Cell Institute, Massachusetts General Hospital and Stanford University Stem Cell Core and others. Mr. Farb-Horch has actively participated in the founding of over 10 life sciences, artificial intelligence and software companies and has had four exits with one billion dollars or more. He has founded and served on the Boards of numerous companies, including Exact Sciences		(NASD: EXAS), Fair Isaac (NYSE: FIC), Redwood Trust (NYSE: RWT), HNC Software (acquired by Fair Isaac), Retek Systems (acquired by Oracle) and Saf-T-Med (acquired by Becton Dickinson). Mr. Farb-Horch has served as President, COO and/or in the senior management of numerous companies, including Thrive Bioscience, Inc., Indevus Pharmaceuticals and Cytyc. Mr. Farb has also been a Trustee for numerous non-profit organizations including North Shore InnoVentures (an incubator/accelerator in the Boston area), Dana Farber Cancer Institute and Asia America Chamber of Commerce. Mr. Farb is a graduate of Harvard University.
9		**Biobot Analytics, Inc**	**Noriko Endo**	**Leveraging wastewater as a window into population health.**
		2011 B.Eng. in Civil Engineering, University of Tokyo, Japan 2014 M.Sci. in Environmental Engineering, Massachusetts institute of Technology,USA 2017 PhD in Environmental Engineering, Massachusetts institute of Technology, USA 2017 Spatial Epidemiologist and Product Manager, Biobot Analytics, USA		Dr. Endo is as engineer who works at the intersection of environmental engineering and public health. She has extensive field experiences in Africa, Asia, and North America on health-related projects, such as malaria transmission, human metabolomics, and antimicrobial resistance.
10		**Canairy**	**Rayees Rahman**	**App based mangement of respiratory disease using cough sounds and machine learning**
		2015 BS, Biology, Hunter College 2016-2019 PhD Candidate, Computational Biolgy, Icahn School of Medicine at Mount Sinai 2018 Co-founder: A.I.chemy, A.I. based drug discovery platform 2019 CEO and Co-Founder of Canairy; Biotechnology Start up		
11		**PORTAL INSTRUMENTS, INC.**	**Andrew Coats**	**Innovation in Drug Delivery: Needle-Free Auto-Injector**
		2008 BS Mechanical Engineering 2008-2011 Cambridge Consultants, Medical Device Engineer 2011-2014 Fractyl Inc., Surgical Device for Diabeaties, Engineer 2014- present Portal Instruments, VP Engineering		